Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, ...

Shares of Bristol Myers Squibb Co. BMY inched 0.90% higher to $55.95 Tuesday, on what proved to be an all-around positive ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

On Tuesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.95 which represents a slight increase of $0.50 or 0.90% from the prior close of $55.45. The stock opened at ...

A weekly summary of insider trading highlighting notable buying and selling by investors, directors and executives. The ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on Bristol-Myers Squibb (BMY – Research Report). The associated price target was raised to $55.00. David Risinger has given ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in November 2024. Samit Hirawat, M.D., Executive Vice President, Chief Medical ...

GHP Investment Advisors Inc. grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 5.9% in the 3rd ...

Lawyers for AstraZeneca , Bristol Myers Squibb and Johnson & Johnson's Janssen on Wednesday urged a federal appeals court in ...